同期多西紫杉醇超分割放疗治疗晚期头颈部癌症：Ⅱ期研究。

Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study.

机构信息

Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.

出版信息

Anticancer Res. 2012 Sep;32(9):4013-8.

Abstract

AIM

To evaluate the value of hyperfractionated radiotherapy with concurrent use of low-dose docetaxel in locally-advanced head and neck squamous cell cancer (HNSCC).

PATIENTS AND METHODS

Patients eligible for this study had confirmed diagnosis of HNSCC stages II (>10 cm(3)) to IVB. Radiotherapy was delivered twice daily at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m(2)) was administered weekly during radiotherapy.

RESULTS

From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n=3). Major grade 3 acute toxicities included mucositis (n=43) and treatment-related pain (n=20). The median follow-up period for surviving patients was 43 months. The 5-year local control rate and overall survival rate were 62.6% and 61.6%, respectively.

CONCLUSION

This modality is a valuable treatment option for the management of locally-advanced HNSCC.

摘要

目的

评估超分割放疗联合低剂量多西他赛治疗局部晚期头颈部鳞状细胞癌（HNSCC）的价值。

患者和方法

本研究纳入了确诊为 HNSCC II 期（>10 cm(3)）至 IVB 期的患者。放疗每天进行两次，每次 1.2 Gy/次，总剂量为 72.0 Gy。多西他赛（10 mg/m(2)）在放疗期间每周给药。

结果

2003 年 3 月至 2008 年 10 月，共治疗了 70 例患者。原发部位包括口咽（n=25）、下咽（n=24）、喉（n=18）和其他部位（n=3）。主要的 3 级急性毒性包括黏膜炎（n=43）和与治疗相关的疼痛（n=20）。生存患者的中位随访时间为 43 个月。5 年局部控制率和总生存率分别为 62.6%和 61.6%。